A Multicenter Open-label Phase 1/1b Study to Evaluate Safety, Feasibility and Early Treatment Effect of Padeliporfin VTP Using Robotic Assisted Bronchoscopy and Cone Beam CT Guidance in Patients With Peripheral Lung Cancer
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Padeliporfin (Primary)
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Adverse reactions
- Sponsors ImPact Biotech; Steba Biotech
Most Recent Events
- 11 Feb 2025 Planned initiation date changed from 28 Dec 2024 to 28 May 2025.
- 30 Oct 2024 Planned initiation date changed from 30 May 2025 to 28 Dec 2024.
- 30 Oct 2024 Status changed from suspended to recruiting.